Prediction: Grail Stock Will Skyrocket to $100 in 1 Year

Grail (GRAL) is down ~40% from its $116.06 all-time high after its NHS England Galleri trial missed the primary endpoint in February, though it showed fewer Stage IV detections and earlier Stage I–II detection. Revenue rose from $93M (2022) to $147M (2025) and is expected to grow at ~25% CAGR to $287M by 2028, largely contingent on FDA premarket approval targeted for late 2026/early 2027. The article argues FDA approval within 12 months could more than double its EV/Revenue multiple and drive upside toward $100.

Analysis

GRAL’s drawdown is less about a single study miss than about the market repricing the odds of near-term reimbursement. The core mistake in the bull case is assuming FDA clearance would automatically translate into broad payer adoption; for multi-cancer screening, coverage is the real monetization event, and that usually lags by quarters to years. That means the stock can look optically cheap on sales while still being expensive relative to the addressable cash-pay niche it can actually penetrate today.

Near term, the weaker read-through is for adjacent liquid-biopsy and screening names: the setback reduces investor appetite for any company selling a ‘category creation’ story ahead of hard outcomes data. That likely helps more proven, reimbursement-backed diagnostics franchises such as EXAS and gives incumbents more time to defend enterprise and payer relationships. The Epic integration is supportive for workflow adoption, but it does not change the fact that ordering volume is not the same as covered demand.

The contrarian point is that the market may be underestimating how much option value remains if management can convert cash-pay traction into a credible PMA path. However, the first-order risk is not scientific death, it is a prolonged limbo where revenue grows but the multiple compresses because the TAM is still being discounted heavily. Falsifier for the bearish view: a clean FDA filing/acceptance plus any sign of coverage dialogue that shortens the reimbursement lag; absent that, the stock is vulnerable to another de-rating on every data or regulatory pause.

Key Decisions for Investors

• Do not chase GRAL on the premise that revenue growth alone supports the current multiple; wait for FDA PMA filing/acceptance or payer-coverage evidence before adding exposure.
• For event-driven books, consider a defined-risk bearish structure in GRAL over the next 3-6 months (put spread rather than outright short) to express reimbursement-delay risk without overcommitting to binary regulatory outcomes.
• Relative-value idea: long EXAS / short GRAL as a cleaner screening-franchise vs. pre-reimbursement optionality trade over 1-3 months; the short leg benefits if the market keeps discounting coverage risk.
• If already long ILMN from the spin-out, treat GRAL weakness as a reminder that the hidden value was never a near-term catalyst; size ILMN on core sequencing economics, not on optional GRAL upside.
• Set an alert for any CMS/private-payer coverage discussion or FDA acceptance date; that is the real catalyst that could justify a re-rate and would invalidate a purely bear-case position.